Insmed (INSM) investor relations material

Recent accomplishments and strategic priorities

• Expanded into three therapeutic areas: respiratory, I&I, and neuro/other, reflecting significant organizational growth over the past decade.

• Two commercial products: ARIKAYCE for nontuberculous mycobacteria and brensocatib for bronchiectasis, both with ongoing clinical and commercial momentum.

• Robust late, mid, and early-stage pipeline across all therapeutic areas, supported by a global workforce of over 1,500 employees.

ARIKAYCE and ENCORE study insights

• ENCORE is a 12-month, 425-patient study powered to show a 4-point change in respiratory symptom score, with data readout expected March-April.

• ARISE and ENCORE studies focus on patient-reported outcomes (PRO) and culture conversion, with ARISE showing promising trends and nominal statistical significance in culture conversion.

• ENCORE results could lead to label expansion in the US and Japan, with a clear win scenario enabling filing before year-end and potential market entry next year.

• Patient populations for potential expansion are significant: 100,000 in the US and 125,000 in Japan for NTM.

brensocatib launch and market strategy

• First and only approved treatment for bronchiectasis, targeting 500,000 diagnosed US patients, with initial focus on 250,000 with two or more exacerbations.

• Real-world data shows increasing documentation of exacerbations, expanding the addressable market.

• Secondary launch targets underdiagnosed COPD/asthma patients, potentially adding hundreds of thousands to millions of eligible patients.

• Achieved nearly $145 million in first full quarter revenue, over 11,000 new patient starts, and 4,000 unique prescribers by end of 2025.

• Projected to reach at least $1 billion in revenue this year, with $5 billion peak sales potential based on current diagnosed patients.